Author: Jennifer Bright, MPA, Executive Director, IVI The promise of a new year offers an opportunity to recall our best moments in 2020 (surely there are a few!) and get excited for what's ahead. For IVI, I've been thinking about the accomplishments not just in 2020, but in the three years since I joined this [...]
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering [...]
Second Webinar in the ISPOR-IVI Series Explores Whether Value Assessments are Up to the Task in the Age of COVID-19
The second part of a five-part webinar series examining value assessment in the COVID-19 era hosted by ISPOR and the Innovation and Value Initiative (IVI) will explore whether the methods on which health economists have relied are up to task or in need of improvement for the pandemic era. Moderated by Lou Garrison, PhD (University [...]
Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine's effectiveness, our society will still have to endure a long process of distribution. I'm personally willing to wait for a vaccine for healthcare workers, the elderly, and [...]
The COVID-19 pandemic is raising new questions about how we approach value assessment. As always, IVI urges experts to use transparency, real world data, and seek consensus. Sam Nussbaum, President of the IVI Board of Directors, shares his thoughts in a commentary in STAT. Read the full commentary here.
Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]